Compound Radar

Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis

Price $34.32
Market cap $4.12B
Next earnings Nov 5, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

55
55/100 Acceptable
  • Financial Health 50
  • Profitability 60
  • Business Quality 75
  • Balance Sheet 50
  • Cash Flow 25

Why this rating?

Health 55/100 — Acceptable

Strongest Business Quality 75/100
Softest Cash Flow 25/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Indivior Pharmaceuticals, Inc. (INDV) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Indivior Pharmaceuticals, Inc. 55/100 (Acceptable) due to high business quality, steady revenue growth, and elevated leverage.

Investment profile

  • Quality High
  • Growth Moderate
  • Balance Sheet Stretched
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 12.68
  • Forward P/E 7.14
  • EV/Revenue 3.31

Profitability

  • Revenue Growth 13.6%
  • Gross Margin 85.7%
  • Operating Margin 46.9%
  • Net Margin 26.7%

Financial strength

  • Cash $222.00M
  • Debt $509.00M
  • Net Cash $-287.00M
  • Free Cash Flow $-94.00M
  • Current Ratio 0.84

Similar companies

Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Drug Manufacturers - Specialty & Generic →

FAQ

How Compound Radar scores and tracks Indivior Pharmaceuticals, Inc. (INDV).

View Methodology & FAQ →